首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   8139篇
  免费   1055篇
  国内免费   319篇
耳鼻咽喉   61篇
儿科学   189篇
妇产科学   80篇
基础医学   834篇
口腔科学   153篇
临床医学   787篇
内科学   968篇
皮肤病学   189篇
神经病学   708篇
特种医学   215篇
外国民族医学   4篇
外科学   549篇
综合类   2002篇
预防医学   566篇
眼科学   234篇
药学   582篇
  15篇
中国医学   404篇
肿瘤学   973篇
  2024年   16篇
  2023年   168篇
  2022年   330篇
  2021年   519篇
  2020年   546篇
  2019年   310篇
  2018年   310篇
  2017年   400篇
  2016年   469篇
  2015年   373篇
  2014年   671篇
  2013年   630篇
  2012年   695篇
  2011年   657篇
  2010年   498篇
  2009年   389篇
  2008年   330篇
  2007年   311篇
  2006年   328篇
  2005年   248篇
  2004年   171篇
  2003年   150篇
  2002年   140篇
  2001年   130篇
  2000年   90篇
  1999年   66篇
  1998年   56篇
  1997年   53篇
  1996年   48篇
  1995年   40篇
  1994年   42篇
  1993年   33篇
  1992年   37篇
  1991年   23篇
  1990年   31篇
  1989年   25篇
  1988年   30篇
  1987年   20篇
  1986年   15篇
  1985年   18篇
  1984年   19篇
  1983年   10篇
  1982年   18篇
  1981年   10篇
  1980年   6篇
  1979年   8篇
  1978年   10篇
  1977年   7篇
  1976年   4篇
  1975年   4篇
排序方式: 共有9513条查询结果,搜索用时 15 毫秒
51.
52.
目的:研究套细胞淋巴瘤(MCL)患者的临床特点及预后相关因素,进一步全面评估病情,探索个体化治疗。方法:回顾性分析2012年1 月至2016年12 月经我院病理科确诊的51例MCL 患者的临床特点、住院20例患者的预后分层和不同化疗方案的近期及远期疗效,并进行随访观察。结果:20例住院治疗患者中,R-Hyper-CVAD组及R-CHOP样组的ORR(分别为100%、100%)均高于其未联合美罗华组(分别为50%、40%);MIPI评分中,低危组ORR为75.0%,明显高于中危组(16.6%);CD5-患者CR、PR均高于CD5+患者;Ki67≥30%患者CR率(20%)大于Ki67<30%组(11%),PR率则相反;Ki67<30%患者3年OS明显高于Ki67≥30%患者,有统计学差异,而PFS无统计学差异;MIPI分组中,低危组3年OS明显高于中高危组,有统计学差异,PFS无统计学差异;美罗华组无论OS还是PFS均高于非美罗华组;Hyper-CVAD组与非Hyper-CVAD组OS、PFS均无统计学差异。结论:美罗华联合化疗治疗MCL的疗效是肯定的,绝大多数患者能够耐受减低剂量的Hyper-CVAD A及B方案化疗,但统计学显示与非Hyper-CVAD组无明显差异,可能与病例数偏少相关,需要更多大样本的循证医学的支持。  相似文献   
53.
目的:分析超声内镜引导下经支气管针吸活检(endobronchial ultrasound-guided transbronchial needle aspiration,EBUS-TBNA)术中肿大纵隔淋巴结的超声图像特点,探讨EBUS-TBNA超声内镜对纵隔淋巴结良恶性的鉴别诊断价值,以期提高EBUS-TBNA对纵隔淋巴结恶性病变的活检率。方法:回顾性分析2014年10月至2018年11月行EBUS-TBNA患者的超声内镜图像。我们使用以下EBUS超声内镜特征来预测淋巴结的良恶:回声,长轴长度,短轴长度,纵横比,形态,边界,淋巴门有无,淋巴结内血流信号分级。将超声检查结果与最终病理结果或临床随访结果进行比较。采用SPSS 20.0软件进行统计学分析,采用logistic回归分析评价肿大淋巴结EBUS-TBNA超声内镜下的特征与良恶性的相关性,以 P<0.05 为标准判定差异有统计学意义。结果:对130例纵隔淋巴结肿大患者的227个淋巴结进行回顾性分析,67.4%的肿大淋巴结被证实为恶性转移。Logistic回归分析显示回声、长轴及短轴的长度、正常淋巴门结构的消失是诊断恶性淋巴结的独立预测因素。结论:纵隔恶性淋巴结具有一定的超声特征,可以通过这些超声特征提高EBUS-TBNA对纵隔恶性淋巴结的检出率。  相似文献   
54.
目的:探讨桥本甲状腺炎(Hashimoto's thyroiditis,HT)对甲状腺乳头状癌(papillary thyroid carcinoma,PTC)的影响。方法:分析882例经甲状腺切除术且病理证实为PTC患者的临床资料,比较PTC合并HT和非合并HT患者临床病理特征和甲状腺功能,分析HT与PTC临床病理特征的相关性。结果:PTC合并HT组239例(27.10%),非合并HT组643例(72.90%),两组间比较,合并HT组女性、癌灶多发、双侧及淋巴结转移比例显著高于非合并HT组,差异均有统计学意义(均P<0.05),而年龄、原发灶直径、远处转移、复发危险度分层及TNM分期均无显著性差异(均P>0.05)。与非合并HT组相比,PTC合并HT组TPOAb、TGAb、TSH水平升高,FT4、FT3水平降低(均P<0.05)。分别进行Logistic回归分析显示:HT与女性、癌灶多发、淋巴结转移呈独立相关(OR值分别为2.690、1.491、1.514,均P<0.05);癌灶多发、原发灶直径>1 cm、合并HT与PTC淋巴结转移独立相关(OR值分别为2.150、2.751、1.465,均P<0.05)。结论:合并HT的PTC患者女性、多灶及淋巴结转移多见,但不影响预后;癌灶多发、原发灶直径>1 cm、合并HT是PTC淋巴结转移的独立危险因素。  相似文献   
55.
《Clinical breast cancer》2020,20(5):e589-e599
PurposeTo investigate the prognosis of single hormone receptor–positive (HR+) breast cancer (estrogen receptor [ER] positive and progesterone receptor [PR] negative, and ERPR+) compared to double HR+ (ER+PR+) and double HR (ERPR) tumors.MethodsWe included 531,605 cases of invasive breast cancer between 1990 and 2012 from the US Surveillance, Epidemiology, and End Results (SEER) database for study and classified cases into 4 phenotypes according to expression of ER and PR: ER+PR+, ER+PR, ERPR+, and ERPR.ResultsOverall, 66,091 ER+PR tumors and 9320 ERPR+ tumors were identified. The clinical characteristics of the ER+PR group were similar to those of the double HR+ group, while those of the ERPR+ and double HR groups were similar. Overall survival of patients with single HR+ tumors was intermediate between that of double HR+ and double HR tumors. However, we observed no differences in disease-specific survival between ERPR+ and ERPR patients. In multivariate analysis, outcomes were similar. Relative to the double HR+ patient group, risk of death in the ER+PR group was higher (hazard ratio, 1.422, 95% confidence interval, 1.394-1.452). However, risk of death was comparable between ERPR+ and ERPR patients (hazard ratio, 1.03; 95% confidence interval, 0.98-1.08). Multivariate Cox proportional analysis showed that survival times of patients in the younger age bracket (< 60 years), those positive for human epidermal growth factor receptor 2 (HER2), and patients with tumor stage I-III were longer in the ERPR+ group.ConclusionDisease-specific survival of single HR+ tumor cases was longer than that of double HR tumors but poorer than double HR+ tumors. However, differences in disease-specific survival were not significant between the ERPR+ and ERPR groups.  相似文献   
56.
目的研究双重排粪造影方式应用在结肠功能性便秘诊断当中的效果。方法文章所选择的调查对象来自2017年10月-2018年12月,均为在此期间本院收治的60例经临床病理诊断确诊为结肠功能性便秘患者,分析双重排粪造影方式和排粪造影的符合性。结果采用双重排粪造影方式诊断结肠功能性便秘59例得到确诊,占98.33%,和排粪造影相比,差异有统计学意义(P<0.05)。结论通过双重排粪造影方式进行结肠功能性便秘诊断,可以有效的提升诊断的效率,对于具体症型的确认也具有重要意义。  相似文献   
57.
ObjectiveWe aimed to provide a meta-analysis of previously published papers on the COVID-19-related clinical features and laboratory findings in children.MethodThis meta-analysis was conducted by using Medline/PubMed, Scopus, Web of Sciences and Google Scholar. Finally, 32 articles were selected for full-text assessment.ResultsThe most frequent symptoms were fever, cough, vomiting, diarrhea, sore throat, and dyspnea. Regarding the combined results of the meta-analysis, fever (46%, 95% CI 40–53%), cough (37%, 95% CI 29–46%), diarrhea (19%, 95% CI 9–28%), and pharyngalgia (13%, 95% CI 5–20%) were the most widely reported symptom. Besides, positive RT-PCR test results (43%, 95% CI 33–53%), low oxygen saturation (38%, 95% CI 25–51%), and elevated D-dimer levels (36%, 95% CI 16–56%) were the most common laboratory findings.ConclusionThis review found that clinical presentations were milder, the prognosis was better, and the mortality rate was lower in children with COVID-19 compared with adult patients; however, children are potential carriers, like adults, and can transmit the infection among the population. Therefore, early identification and intervention in pediatric patients with COVID-19 are essential in order to control the pandemic. Moreover, gastrointestinal symptoms were more common symptoms among children.  相似文献   
58.
Our institution has performed microbiological diagnosis of Tropheryma whipplei since 2001, initially with a PCR targeting 16S rRNA before the development of a quantitative PCR in 2012. Here we report the clinical characteristics of a cohort of patients suffering from Whipple disease (WD) and evaluate the impact of these molecular techniques. Patients with a positive PCR for T. whipplei between 2001 and 2016 were retrospectively collected from microbiological databases. Two infectious diseases specialists reviewed their medical records and classified them as definite WD, probable WD or carriage of T. whipplei without disease. A total of 1153 samples were tested for T. whipplei; 76 samples taken from 36 patients were positive. Fifteen were considered as presenting a definite WD, seven as a probable WD and 14 as carriers. Median age was 56.4 years (extremes, 6.6–76.1). Median time from symptoms to diagnosis was 3 years (2.5 months to 13.3 years). About 60% were immunosuppressed. The most frequent clinical presentations were joint pain (16/22), weight loss (15/22) and/or digestive tract disorder (15/22); 41% had neurological manifestations, 32% pulmonary involvement and 32% lymphadenopathies. Bacterial load in faeces or saliva were 88 425 copies/mL (IQR 6175-292 725) in definite and probable WD and 311 copies/mL (IQR 253–2090) in carriers, respectively. We observed a 90% PPV above 32 200 copies/mL in faeces. WD is a chronic multisystemic disease with frequent pulmonary involvement. Underlying immunodeficiency is commonly observed leading to more complex clinical presentation. Positive T. whipplei PCR in both stool and saliva has a high positive predictive value. Moreover, patients with WD present higher bacterial load in faeces with a threshold of >32 200 copies/mL predicting ongoing infection.  相似文献   
59.
Neoadjuvant programmed cell death protein 1 (PD-1) blockade exhibits promising efficacy in patients with mismatch repair deficient (dMMR) colorectal cancer (CRC). However, discrepancies between radiological and histological findings have been reported in the PICC phase II trial (NCT 03926338). Therefore, we strived to discern radiological features associated with pathological complete response (pCR) based on computed tomography (CT) images. Data were obtained from the PICC trial that included 36 tumors from 34 locally advanced dMMR CRC patients, who received neoadjuvant PD-1 blockade for 3 months. Among the 36 tumors, 28 (77.8%) tumors achieved pCR. There were no statistically significant differences in tumor longitudinal diameter, the percentage change in tumor longitudinal diameter from baseline, primary tumor sidedness, clinical stage, extramural venous invasion status, intratumoral calcification, peritumoral fat infiltration, intestinal fistula and tumor necrosis between the pCR and non-pCR tumors. Otherwise, tumors with pCR had smaller posttreatment tumor maximum thickness (median: 10 mm vs 13 mm, P = .004) and higher percentage decrease in tumor maximum thickness from baseline (52.9% vs 21.6%, P = .005) compared to non-pCR tumors. Additionally, a higher proportion of the absence of vascular sign (P = .003, odds ratio [OR] = 25.870 [95% CI, 1.357-493.110]), nodular sign (P < .001, OR = 189.000 [95% CI, 10.464-3413.803]) and extramural enhancement sign (P = .003, OR = 21.667 [2.848-164.830]) was observed in tumors with pCR. In conclusion, these CT-defined radiological features may have the potential to serve as valuable tools for clinicians in identifying patients who have achieved pCR after neoadjuvant PD-1 blockade, particularly in individuals who are willing to adopt a watch-and-wait strategy.  相似文献   
60.
目的 分析杭州地区蜘蛛咬伤病例的临床特征。方法 回顾性分析2020年4月~2021年11月因蜘蛛咬伤收治我科住院患者71例,对患者人群特征、临床表现、实验室检查结果、诊疗情况、转归进行分析、总结。结果 被咬伤人群主要为中青年,每年5~9月为发病高峰期,咬伤部位主要在双下肢,71例患者中58例患者仅有局部症状,13例患者除了局部症状还伴有全身毒性反应发症。 结论:杭州地区蜘蛛毒性较小,伤人后主要以局部症状为主,合理的局部和全身治疗均能得到痊愈。  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号